Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cartesian Therapeutics, Inc.RNAC · Entity 6015 | Director · 10% owner | January 02, 2026 | January 06, 2026 |
| Tectonic Therapeutic, Inc.TECX · Entity 5328 | Director · 10% owner | June 09, 2026 | June 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cartesian Therapeutics, Inc.
Report date January 02, 2026 · Filed January 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,646,285 |
Reported balance
After 2026-01-02 transaction · row 1
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 2,600 · Balance 8,646,285 F1: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest in full on January 2, 2027. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.76 · Expires 2036-01-01 | Direct | 7,800 |
Reported balance
After 2026-01-02 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-01-02 · Grant · Acquired 7,800 · Balance 7,800 |
| Common StockSEC Table I · non-derivative | IndirectBy wife | 330,695 |
Reported balance
Holding disclosure · report date 2026-01-02 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 330,695 |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 656,513 |
Reported balance
Holding disclosure · report date 2026-01-02 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 656,513 F2: Held by TAS Partners LLC. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest in full on January 2, 2027.
F2: Held by TAS Partners LLC. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any.
Tectonic Therapeutic, Inc.
Report date June 09, 2026 · Filed June 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.56 · Expires 2036-06-08 | Direct | 10,200 |
Reported balance
After 2026-06-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-09 · Grant · Acquired 10,200 · Balance 10,200 F1: The option shall vest in full on the earliest of (i) June 9, 2027, (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, or (iii) a "Change in Control" (as defined in the Issuer's 2024 Equity Incentive Plan) of the Issuer, subject in each case, to the Reporting Person providing continuous service to the Issuer on each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option shall vest in full on the earliest of (i) June 9, 2027, (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, or (iii) a "Change in Control" (as defined in the Issuer's 2024 Equity Incentive Plan) of the Issuer, subject in each case, to the Reporting Person providing continuous service to the Issuer on each such date.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Morphic Holding, Inc.
Report date August 16, 2024 · Filed August 20, 2024
Section 16 reporting ended · disclosed 2024-08-20. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-08-16 transaction · row 1
1 source rowRow 1 · 2024-08-16 · Other · Disposed 4,608,052 · Balance 0 F1: On July 7, 2024, Morphic Holding, Inc., a Delaware corporation (the "Issuer" or the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Eli Lilly and Company, an Indiana corporation (the "Parent"), and Rainier Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. F2: (Continued from Footnote 1) Upon the closing (the "Closing") of the Merger on August 16, 2024, each share of the Company's Common Stock, par value $0.0001 per share ("Common Stock"), was either (x) purchased by Purchaser for $57.00 per share (the "Offer Price"), without interest, less any applicable tax withholding or (y) automatically converted into the right to receive the Offer Price in cash without interest, less any applicable tax withholding. |
| Common StockSEC Table I · non-derivative | IndirectSee TAS Partners LLC | 0 |
Reported balance
After 2024-08-16 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2024-08-16 · Other · Disposed 2,768,893 · Balance 0 F1: On July 7, 2024, Morphic Holding, Inc., a Delaware corporation (the "Issuer" or the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Eli Lilly and Company, an Indiana corporation (the "Parent"), and Rainier Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. F2: (Continued from Footnote 1) Upon the closing (the "Closing") of the Merger on August 16, 2024, each share of the Company's Common Stock, par value $0.0001 per share ("Common Stock"), was either (x) purchased by Purchaser for $57.00 per share (the "Offer Price"), without interest, less any applicable tax withholding or (y) automatically converted into the right to receive the Offer Price in cash without interest, less any applicable tax withholding. F3: The reporting person is the manager of TAS Partners LLC and has sole voting and dispositive power over such shares. |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 0 |
Reported balance
After 2024-08-16 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2024-08-16 · Other · Disposed 42,873 · Balance 0 F1: On July 7, 2024, Morphic Holding, Inc., a Delaware corporation (the "Issuer" or the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Eli Lilly and Company, an Indiana corporation (the "Parent"), and Rainier Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. F2: (Continued from Footnote 1) Upon the closing (the "Closing") of the Merger on August 16, 2024, each share of the Company's Common Stock, par value $0.0001 per share ("Common Stock"), was either (x) purchased by Purchaser for $57.00 per share (the "Offer Price"), without interest, less any applicable tax withholding or (y) automatically converted into the right to receive the Offer Price in cash without interest, less any applicable tax withholding. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.76 · Expires 2029-04-11 | Direct | 0 |
Reported balance
After 2024-08-16 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-08-16 · Disposition to issuer · Disposed 4,288 · Balance 0 F5: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F4: The Company Stock Option ("Option") is fully vested. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.00 · Expires 2029-06-26 | Direct | 0 |
Reported balance
After 2024-08-16 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-08-16 · Disposition to issuer · Disposed 24,000 · Balance 0 F5: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F4: The Company Stock Option ("Option") is fully vested. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.72 · Expires 2029-12-05 | Direct | 0 |
Reported balance
After 2024-08-16 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2024-08-16 · Disposition to issuer · Disposed 90,000 · Balance 0 F5: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F4: The Company Stock Option ("Option") is fully vested. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.96 · Expires 2030-06-18 | Direct | 0 |
Reported balance
After 2024-08-16 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2024-08-16 · Disposition to issuer · Disposed 12,000 · Balance 0 F5: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F4: The Company Stock Option ("Option") is fully vested. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $64.79 · Expires 2031-06-16 | Direct | 0 |
Reported balance
After 2024-08-16 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2024-08-16 · Disposition to issuer · Disposed 9,996 · Balance 0 F5: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F4: The Company Stock Option ("Option") is fully vested. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.49 · Expires 2032-06-08 | Direct | 0 |
Reported balance
After 2024-08-16 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2024-08-16 · Disposition to issuer · Disposed 17,550 · Balance 0 F5: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F4: The Company Stock Option ("Option") is fully vested. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $56.47 · Expires 2033-05-31 | Direct | 0 |
Reported balance
After 2024-08-16 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2024-08-16 · Disposition to issuer · Disposed 12,535 · Balance 0 F5: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F4: The Company Stock Option ("Option") is fully vested. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.52 · Expires 2034-06-03 | Direct | 0 |
Reported balance
After 2024-08-16 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2024-08-16 · Disposition to issuer · Disposed 23,168 · Balance 0 F5: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F6: The Option will vest in full on the earlier of (a) June 04, 2025 and (b) the next annual meeting of the issuer's stockholders, subject to the reporting person's provision of service to the issuer on the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: On July 7, 2024, Morphic Holding, Inc., a Delaware corporation (the "Issuer" or the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Eli Lilly and Company, an Indiana corporation (the "Parent"), and Rainier Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent.
F2: (Continued from Footnote 1) Upon the closing (the "Closing") of the Merger on August 16, 2024, each share of the Company's Common Stock, par value $0.0001 per share ("Common Stock"), was either (x) purchased by Purchaser for $57.00 per share (the "Offer Price"), without interest, less any applicable tax withholding or (y) automatically converted into the right to receive the Offer Price in cash without interest, less any applicable tax withholding.
F3: The reporting person is the manager of TAS Partners LLC and has sole voting and dispositive power over such shares.
F4: The Company Stock Option ("Option") is fully vested.
F5: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof.
F6: The Option will vest in full on the earlier of (a) June 04, 2025 and (b) the next annual meeting of the issuer's stockholders, subject to the reporting person's provision of service to the issuer on the vesting date.
Scholar Rock Holding Corp
Report date December 10, 2019 · Filed December 12, 2019
Section 16 reporting ended · disclosed 2019-12-12. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,376,567 |
Reported balance
After 2019-12-10 transaction · row 1
1 source rowRow 1 · 2019-12-10 · Gift · Disposed 296,000 · Balance 2,376,567 F1: Represents shares of the Company's common stock transfered as a gift for no consideration to the Institute of Protein Innovation, a not-for-profit research institution. |
| Common StockSEC Table I · non-derivative | IndirectBy TAS Partners, LLC | 580,855 |
Reported balance
Holding disclosure · report date 2019-12-10 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 580,855 F2: Timothy Springer is the Managing Member of TAS Partners LLC. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of the Company's common stock transfered as a gift for no consideration to the Institute of Protein Innovation, a not-for-profit research institution.
F2: Timothy Springer is the Managing Member of TAS Partners LLC.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 29, 2018 Filed Jun 1, 2018 01:41 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | ConversionSeries B Preferred · Derivative | 2,094,875 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-18-037312 · a4.xml · derivative · entry 11 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 733,808 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Preferred Stock automatically converted into Common Stock, for no payment or additional consideration, on a 2.8548-for-1 basis at the closing of the Issuer's initial public offering on May 29, 2018 and had no expiration date. F1 · price: Each share of Preferred Stock automatically converted into Common Stock, for no payment or additional consideration, on a 2.8548-for-1 basis at the closing of the Issuer's initial public offering on May 29, 2018 and had no expiration date. F1 · derivative.exercise_date: Each share of Preferred Stock automatically converted into Common Stock, for no payment or additional consideration, on a 2.8548-for-1 basis at the closing of the Issuer's initial public offering on May 29, 2018 and had no expiration date. F1 · derivative.expiration_date: Each share of Preferred Stock automatically converted into Common Stock, for no payment or additional consideration, on a 2.8548-for-1 basis at the closing of the Issuer's initial public offering on May 29, 2018 and had no expiration date. Read SEC document |
| May 29, 2018 Filed Jun 1, 2018 01:41 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | ConversionSeries A-3 Preferred · Derivative | 1,449,275 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-18-037312 · a4.xml · derivative · entry 10 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 507,662 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Preferred Stock automatically converted into Common Stock, for no payment or additional consideration, on a 2.8548-for-1 basis at the closing of the Issuer's initial public offering on May 29, 2018 and had no expiration date. F1 · price: Each share of Preferred Stock automatically converted into Common Stock, for no payment or additional consideration, on a 2.8548-for-1 basis at the closing of the Issuer's initial public offering on May 29, 2018 and had no expiration date. F1 · derivative.exercise_date: Each share of Preferred Stock automatically converted into Common Stock, for no payment or additional consideration, on a 2.8548-for-1 basis at the closing of the Issuer's initial public offering on May 29, 2018 and had no expiration date. F1 · derivative.expiration_date: Each share of Preferred Stock automatically converted into Common Stock, for no payment or additional consideration, on a 2.8548-for-1 basis at the closing of the Issuer's initial public offering on May 29, 2018 and had no expiration date. Read SEC document |
| May 29, 2018 Filed Jun 1, 2018 01:41 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | ConversionSeries A-2 Preferred · Derivative | 1,491,792 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-18-037312 · a4.xml · derivative · entry 9 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 522,556 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Preferred Stock automatically converted into Common Stock, for no payment or additional consideration, on a 2.8548-for-1 basis at the closing of the Issuer's initial public offering on May 29, 2018 and had no expiration date. F1 · price: Each share of Preferred Stock automatically converted into Common Stock, for no payment or additional consideration, on a 2.8548-for-1 basis at the closing of the Issuer's initial public offering on May 29, 2018 and had no expiration date. F1 · derivative.exercise_date: Each share of Preferred Stock automatically converted into Common Stock, for no payment or additional consideration, on a 2.8548-for-1 basis at the closing of the Issuer's initial public offering on May 29, 2018 and had no expiration date. F1 · derivative.expiration_date: Each share of Preferred Stock automatically converted into Common Stock, for no payment or additional consideration, on a 2.8548-for-1 basis at the closing of the Issuer's initial public offering on May 29, 2018 and had no expiration date. Read SEC document |
| May 29, 2018 Filed Jun 1, 2018 01:41 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | ConversionSeries A-1 Preferred · Derivative | 1,000,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-18-037312 · a4.xml · derivative · entry 8 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 350,287 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Preferred Stock automatically converted into Common Stock, for no payment or additional consideration, on a 2.8548-for-1 basis at the closing of the Issuer's initial public offering on May 29, 2018 and had no expiration date. F1 · price: Each share of Preferred Stock automatically converted into Common Stock, for no payment or additional consideration, on a 2.8548-for-1 basis at the closing of the Issuer's initial public offering on May 29, 2018 and had no expiration date. F1 · derivative.exercise_date: Each share of Preferred Stock automatically converted into Common Stock, for no payment or additional consideration, on a 2.8548-for-1 basis at the closing of the Issuer's initial public offering on May 29, 2018 and had no expiration date. F1 · derivative.expiration_date: Each share of Preferred Stock automatically converted into Common Stock, for no payment or additional consideration, on a 2.8548-for-1 basis at the closing of the Issuer's initial public offering on May 29, 2018 and had no expiration date. Read SEC document |
| May 29, 2018 Filed Jun 1, 2018 01:41 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | ConversionCommon Stock | 275,903 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-18-037312 · a4.xml · nonDerivative · entry 7 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By TAS Partners, LLC Disclosed balance after: 275,903 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Preferred Stock automatically converted into Common Stock, for no payment or additional consideration, on a 2.8548-for-1 basis at the closing of the Issuer's initial public offering on May 29, 2018 and had no expiration date. F2 · ownership.nature: Timothy Springer is the Managing Member of TAS Partners, LLC. Read SEC document |
| May 29, 2018 Filed Jun 1, 2018 01:41 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | PurchaseCommon Stock | 71,428 | $14.00 | $999,992.00 |
DisclosureSEC source: 0001104659-18-037312 · a4.xml · nonDerivative · entry 6 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,273,519 Read SEC document |
| May 29, 2018 Filed Jun 1, 2018 01:41 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | ConversionCommon Stock | 299,632 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-18-037312 · a4.xml · nonDerivative · entry 5 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,202,091 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Preferred Stock automatically converted into Common Stock, for no payment or additional consideration, on a 2.8548-for-1 basis at the closing of the Issuer's initial public offering on May 29, 2018 and had no expiration date. Read SEC document |
| May 29, 2018 Filed Jun 1, 2018 01:41 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | ConversionCommon Stock | 733,808 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-18-037312 · a4.xml · nonDerivative · entry 4 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,902,459 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Preferred Stock automatically converted into Common Stock, for no payment or additional consideration, on a 2.8548-for-1 basis at the closing of the Issuer's initial public offering on May 29, 2018 and had no expiration date. Read SEC document |
| May 29, 2018 Filed Jun 1, 2018 01:41 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | ConversionCommon Stock | 507,662 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-18-037312 · a4.xml · nonDerivative · entry 3 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,168,651 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Preferred Stock automatically converted into Common Stock, for no payment or additional consideration, on a 2.8548-for-1 basis at the closing of the Issuer's initial public offering on May 29, 2018 and had no expiration date. Read SEC document |
| May 29, 2018 Filed Jun 1, 2018 01:41 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | ConversionCommon Stock | 522,556 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-18-037312 · a4.xml · nonDerivative · entry 2 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,660,989 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Preferred Stock automatically converted into Common Stock, for no payment or additional consideration, on a 2.8548-for-1 basis at the closing of the Issuer's initial public offering on May 29, 2018 and had no expiration date. Read SEC document |
| May 29, 2018 Filed Jun 1, 2018 01:41 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | ConversionCommon Stock | 350,287 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-18-037312 · a4.xml · nonDerivative · entry 1 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,138,433 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Preferred Stock automatically converted into Common Stock, for no payment or additional consideration, on a 2.8548-for-1 basis at the closing of the Issuer's initial public offering on May 29, 2018 and had no expiration date. Read SEC document |
| November 14, 2017 Filed Nov 16, 2017 22:14 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | PurchaseCommon Stock | 57,598 | $9.27 | $534,094.73 |
DisclosureSEC source: 0001638599-17-001145 · doc4_5080.xml · nonDerivative · entry 1 SPRINGER TIMOTHY A · CIK 0001055624 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 461,349 F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $9.11 to $9.625, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| November 10, 2017 Filed Nov 13, 2017 23:19 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | PurchaseCommon Stock | 4,752 | $9.03 | $42,905.81 |
DisclosureSEC source: 0001638599-17-001129 · doc4_5057.xml · nonDerivative · entry 6 SPRINGER TIMOTHY A · CIK 0001055624 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 403,751 F5 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $8.83 to $9.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| November 10, 2017 Filed Nov 13, 2017 23:19 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | PurchaseCommon Stock | 21,586 | $9.04 | $195,191.41 |
DisclosureSEC source: 0001638599-17-001129 · doc4_5057.xml · nonDerivative · entry 5 SPRINGER TIMOTHY A · CIK 0001055624 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 398,999 F4 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $8.85 to $9.39, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| November 10, 2017 Filed Mar 29, 2019 20:15 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | PurchaseCommon Stock | 4,752 | $9.03 | $42,905.81 |
DisclosureSEC source: 0001055624-19-000002 · wf-form4_155389051295591.xml · nonDerivative · entry 1 SPRINGER TIMOTHY A · CIK 0001055624 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 9,752 F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $8.83 to $9.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. F2 · ownership.direct: Reflects a correction to the Reporting Person's end of period holdings to reflect that 4,752 shares previously shown as held directly are held indirectly by the reporting person's wife. F2 · ownership.nature: Reflects a correction to the Reporting Person's end of period holdings to reflect that 4,752 shares previously shown as held directly are held indirectly by the reporting person's wife. Read SEC document |
| November 09, 2017 Filed Nov 13, 2017 23:19 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | PurchaseCommon Stock | 100 | $9.78 | $978.00 |
DisclosureSEC source: 0001638599-17-001129 · doc4_5057.xml · nonDerivative · entry 4 SPRINGER TIMOTHY A · CIK 0001055624 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 5,000 Read SEC document |
| November 09, 2017 Filed Nov 13, 2017 23:19 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | PurchaseCommon Stock | 4,900 | $9.33 | $45,702.79 |
DisclosureSEC source: 0001638599-17-001129 · doc4_5057.xml · nonDerivative · entry 3 SPRINGER TIMOTHY A · CIK 0001055624 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 4,900 F3 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $8.75 to $9.735, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| November 09, 2017 Filed Nov 13, 2017 23:19 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | PurchaseCommon Stock | 900 | $9.74 | $8,766.63 |
DisclosureSEC source: 0001638599-17-001129 · doc4_5057.xml · nonDerivative · entry 2 SPRINGER TIMOTHY A · CIK 0001055624 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 377,413 F2 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $9.72 to $9.79, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| November 09, 2017 Filed Nov 13, 2017 23:19 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | PurchaseCommon Stock | 21,100 | $9.33 | $196,892.54 |
DisclosureSEC source: 0001638599-17-001129 · doc4_5057.xml · nonDerivative · entry 1 SPRINGER TIMOTHY A · CIK 0001055624 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 376,513 F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $8.72 to $9.71, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 27, 2017 Filed Jun 28, 2017 20:36 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | PurchaseWarrant (right to buy) · Derivative | 79,130 | $0.13 Strike: $17.71 | $9,891.25 |
DisclosureSEC source: 0001638599-17-000662 · doc4_4824.xml · derivative · entry 4 SPRINGER TIMOTHY A · CIK 0001055624 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,130 Underlying: Common Stock · 79,130 shares Expires 2022-06-27 Read SEC document |
| June 27, 2017 Filed Jun 28, 2017 20:36 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | PurchaseCommon Stock | 338,791 | $17.71 | $5,999,988.61 |
DisclosureSEC source: 0001638599-17-000662 · doc4_4824.xml · nonDerivative · entry 1 SPRINGER TIMOTHY A · CIK 0001055624 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 355,413 Read SEC document |
| June 16, 2017 Filed Jun 20, 2017 20:41 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantStock Option (Right to Buy) · Derivative | 6,410 | $0.00 Strike: $17.47 | $0.00 |
DisclosureSEC source: 0001638599-17-000638 · doc4_4809.xml · derivative · entry 1 SPRINGER TIMOTHY A · CIK 0001055624 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,410 Underlying: Common Stock · 6,410 shares Expires 2027-06-15 F1 · derivative.exercise_date: The option vests in full on the earlier of June 16, 2018 or the day immediately prior to the company's 2018 annual meeting of shareholders. Read SEC document |
| June 01, 2017 Filed Jun 2, 2017 20:05 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | PurchaseCommon Stock | 518 | $13.75 | $7,122.50 |
DisclosureSEC source: 0001638599-17-000527 · doc4_4755.xml · nonDerivative · entry 1 SPRINGER TIMOTHY A · CIK 0001055624 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,622 Read SEC document |
| May 18, 2017 Filed May 19, 2017 20:06 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | PurchaseCommon Stock | 4,860 | $14.00 | $68,040.00 |
DisclosureSEC source: 0001144204-17-028639 · v467529_4.xml · nonDerivative · entry 2 SPRINGER TIMOTHY A · CIK 0001055624 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,104 Read SEC document |
| May 17, 2017 Filed May 19, 2017 20:06 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | PurchaseCommon Stock | 11,244 | $14.01 | $157,483.46 |
DisclosureSEC source: 0001144204-17-028639 · v467529_4.xml · nonDerivative · entry 1 SPRINGER TIMOTHY A · CIK 0001055624 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,244 F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $13.64 to $14.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.